Related Experiment Video
Updated: Apr 29, 2026
Analysis of Protein-protein Interactions and Co-localization Between Components of Gap, Tight, and Adherens Junctions in Murine Mammary Glands
Published on: May 30, 2017
Expression of CLDN18.2 in Invasive Mucinous Adenocarcinomas of the Lung
Kunio Mochizuki1, Ippei Tahara1, Tomohiro Inoue1
1Department of Pathology, University of Yamanashi, Yamanashi, Japan.
Background/Aim:
Invasive mucinous adenocarcinoma (IMA) of the lung is a rare adenocarcinoma subtype with abundant intracytoplasmic mucin and poor response to standard non-small cell lung cancer chemotherapy. Molecularly targeted therapies may be useful in IMA. Zolbetuximab is a chimeric IgG1 monoclonal antibody against Claudin-18.2 (CLDN18.2) that induces cell death in CLDN18.2-positive gastric and gastro-esophageal junction adenocarcinomas. If lung IMAs also highly express CLDN18.2, they may be candidates for zolbetuximab treatment. This study evaluated CLDN18.2 expression in lung IMAs by immunohistochemistry.
Materials And Methods:
We analyzed surgically resected samples comprising 30 IMAs, 10 non-mucinous adenocarcinomas (NMAs), 10 squamous cell carcinomas (SqCCs), 10 small cell carcinomas (SmCCs), 9 large cell carcinomas (LCCs), and 10 large cell neuroendocrine carcinomas (LCNECs) of the lung.
Results:
We confirmed CLDN18.2 expression (H-score ≥50 points) in 77% of IMA samples. Its expression was rarely observed in other histological types of lung cancer.
Conclusion:
CLDN18.2 is frequently expressed in IMAs but rarely in other major lung cancer subtypes, suggesting that zolbetuximab may represent a promising targeted therapy for IMA.
